CLLS (Cellectis) Price-to-Funds-From-Operations: (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLLS Cellectis SA CLLS
58 GF Score
Price $3.42
GF Value $3.00
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cellectis Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.

CLLS
58GF Score
Cellectis SA CLLS
Price-to-Funds-From-Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (CLLS) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of $3.42 is trading 14% above its estimated GF Value™ of $3.00. GuruFocus considers Cellectis to be Modestly Overvalued.

Key valuation signals for CLLS:

  • Price-to-Funds-From-Operations:
  • GF Value™: $3.00 vs. price of $3.42 (14% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the CLLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
58GF Score

Get the complete analysis for CLLS

Price-to-Funds-From-Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.42
Price
$3.00
GF Value